Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $298.3 million.

  • Amphastar Pharmaceuticals' Accumulated Depreciation & Amortization rose 294596.14% to $298.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $298.3 million, marking a year-over-year increase of 294596.14%. This contributed to the annual value of $271.6 million for FY2024, which is 95523.95% up from last year.
  • Amphastar Pharmaceuticals' Accumulated Depreciation & Amortization amounted to $298.3 million in Q3 2025, which was up 294596.14% from $290.5 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Accumulated Depreciation & Amortization ranged from a high of $298.3 million in Q3 2025 and a low of $2.5 million during Q1 2021
  • Over the past 5 years, Amphastar Pharmaceuticals' median Accumulated Depreciation & Amortization value was $9.7 million (recorded in 2024), while the average stood at $65.8 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Accumulated Depreciation & Amortization skyrocketed by 180.89% in 2024 and then surged by 294596.14% in 2025.
  • Amphastar Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $10.2 million in 2021, then rose by 23.2% to $12.6 million in 2022, then skyrocketed by 104.31% to $25.7 million in 2023, then surged by 955.24% to $271.6 million in 2024, then rose by 9.83% to $298.3 million in 2025.
  • Its last three reported values are $298.3 million in Q3 2025, $290.5 million for Q2 2025, and $280.0 million during Q1 2025.